Highest-materiality recent filing
Enveric shareholders approve reverse stock split, reject increase in authorized shares
Reverse stock split (1:5 to 1:15) approved: 793,344 for, 190,175 against, 8,309 abstentions.
Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M
Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.
Enveric closes $5M private placement of shares and warrants with potential $8.9M additional proceeds
Gross proceeds of ~$5M from sale of 2.22M shares/pre-funded warrants; potential $8.9M more if warrants exercised.
Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND
Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.
Enveric Biosciences raises $3.1M via warrant exercise inducement at $7.05 per share
Gross proceeds of ~$3.1M from cash exercise of 426,390 existing warrants at reduced price of $7.05/sh.
Enveric shareholders approve 50x increase in authorized shares and reverse split authority
Approved increase in authorized common shares from 100M to 5B (50x) at board discretion.
Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026
Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.
Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency
Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.
Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants
Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.
Enveric Biosciences receives Nasdaq deficiency notice for failing minimum equity requirement
Nasdaq notified Enveric on Aug 26, 2025 that stockholders' equity of $2.18M as of June 30, 2025 is below $2.5M minimum.
Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026
Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.
Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting
Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.
Enveric Biosciences dismisses Marcum LLP, engages CBIZ CPAs as new auditor effective April 14
Marcum LLP dismissed as independent auditor; CBIZ CPAs P.C. engaged effective April 14, 2025 for FY 2025.
Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M
Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.
Enveric Biosciences regains Nasdaq bid price compliance
Received notice from Nasdaq on March 4, 2025 that it complied with Listing Rule 5550(a)(2).
Enveric Biosciences announces 1-for-15 reverse stock split effective Jan 27, 2025
Shareholders approved reverse split at a special meeting on Jan 17, 2025; ratio range 1:10 to 1:100.
Enveric Biosciences receives Nasdaq delisting notice on Nov 20 for bid price failure
Nasdaq notified Enveric on Nov 20, 2024, that it failed to meet the $1.00 minimum bid price requirement by the Nov 12 compliance deadline.
Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties
Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.
Enveric Biosciences reports Q2 2024 net loss of $1.7M; prioritizes EB-003 as lead candidate
Net loss of $1.7M ($0.23/share) vs $6.4M loss in Q2 2023; cash on hand $3.5M.
Enveric Biosciences receives Nasdaq delisting notice for bid price below $1.00
Closing bid price below $1.00 for 30 consecutive business days as of May 16, 2024.
Net loss $3.44M ($1.46 per share) vs $8.80M ($4.89 per share) in Q4 2022.
Three non-binding term sheets signed with undisclosed biotech for exclusive global out-licenses of three compound classes.
Enveric Biosciences gets Nasdaq extension to meet $2.5M equity requirement by May 20, 2024
Nasdaq granted extension to May 20, 2024 to meet minimum $2,500,000 stockholders' equity requirement.
Enveric Biosciences cuts 50% of workforce (7 positions) to reduce costs
Approximately 7 positions eliminated, representing ~50% of global workforce, to streamline operations.
Enveric corrects EB-003 binding affinity data, shows 1000x greater potency than previously reported
EB-003 exhibits 5-HT2A partial agonism with Ki of 0.2 µM (corrected from 0.2 mM) – 1000x higher binding affinity.
the Company terminated the employment contract of Mr. Kanubaddi without Cause (as defined in the Employment Agreement), the President and Chief Operating Officer of the Company, to be effective June 17, 2023
On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).
Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.
On September 9, 2022, Robert Dickey IV was appointed as the Chief Financial Officer (“CFO”) of the Company, to serve on an interim basis, effective September 9, 2022.
On July 13, 2022, Frank Pasqualone was appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc. (the “Company”), to serve as a director of the Board, to fill a vacancy as a result of the increase in the size of the Board from eight to nine persons, effective as of the same date
On June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc.
On June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences, Inc.
On May 3, 2022, Brad Thompson, PhD resigned from the board of directors (the “ Board ”) of Enveric Biosciences, Inc. (the “ Company ”).
On November 15, 2021, Enveric Biosciences, Inc. (the “Company”) appointed Avani Kanubaddi, the Chief Operating Officer of the Company, to serve as the Company’s President, effective as of November 15, 2021.
the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors
assigned David Johnson, 63, the title of Executive Chairman of the Company, and removed the title of Chief Executive Officer.
Max materiality 0.85 · Median 0.57 · Most common event other_material